langtids - eller middellangtidsvirkende insulin, et lignende fald i HbA1c som patienter, der tager subkutant insulin alene.
In clinical trials in type 1 diabetes, patients using a regimen of EXUBERA in combination with long- or intermediate-acting insulin had similar reductions in HbA1c compared with patients taking subcutaneous insulin alone.